INTRODUCTION
Raynaud phenomenon (RP) is a cold or stress induced vasospasm of thermoregulatory vessels in the skin and tissues of the digits. Nitrates have long been used as a therapy for both primary and secondary RP. Organic nitrates interact with their receptors located on smooth muscle cells of blood vessels and are converted to nitric oxide which increases cyclic guanosine monophosphate (cGMP) causing vasodilatation of venous and arterial vessels. Various formulations of nitroglycerine exist including ointment, transdermal patches, sublingual tablets and tape. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] There has been evidence of improvement in Raynaud attack severity and frequency, 8 12 skin temperature (ST) 3 13 14 and blood flow (BF) 1 4 9 11 with the use of nitrates. Topical nitroglycerine is often prescribed to patients, but its use has been limited by side effects including headache, flushing and nitrate tolerance. In some studies, the dropout rate due to adverse events has been as high as 20%, with headaches in as many as 80% of those treated. 12 The object of this study was to examine the tolerability and efficacy of a novel preparation of nitroglycerine gel that has little or no systemic absorption in the treatment of RP. MQX-503 is a microemulsion formulation of nitroglycerine, approximately half water and half organic, with a surfactant system designed for rapid, non-irritating local delivery of the active agent topically on the skin.
METHODS Design
This study is a laboratory-based, randomised, double-blind, placebo-controlled, cross-over, dose evaluation protocol with digital BF as the main outcome measure. Upon study enrolment subjects were randomly assigned to one of six sequences, with sequence assignment determining the order in which the different treatments (placebo gel, 0.5% nitroglycerine, 1.25% nitroglycerine) were applied. Each subject received each drug preparation twice, completing six study periods during three visits with two assessments per visit. This study was approved by the Institutional Review Boards of both participating institutions and all subjects signed written consent forms prior to study entry.
Subjects
Subjects with primary or secondary RP were recruited from two academic rheumatology centres ( Johns Hopkins University and University of Washington). Subjects had a clinical diagnosis of RP as determined by a history of cold sensitivity with pallor and/or cyanosis of the digits or an observed event by the study physician. Subjects were required to discontinue other vasodilator therapies 2 weeks prior to the start of the study. Subjects were excluded if they were currently using any nitrate medication or medication known to interact with nitroglycerine or were unable to discontinue their vasodilator therapy safely (such as ongoing digital ischaemia) or had open skin ulcerations. Subjects with migraine or cluster headaches and those with medical conditions where the administration of nitrate medications may be contraindicated were excluded.
Outcome assessment
The primary outcome measure was time to achieve baseline BF as measured by laser Doppler and defined as the first time after cold challenge when the subject had a BF value greater or equal to the baseline value. BF was averaged over the second through fourth digits for each assessment point. Secondary outcome measures were: proportion achieving baseline BF, time to achieve 50% and 70% baseline ST and pain, numbness and tingling scores measured on a 0-10 visual analogue scale.
Safety assessment
Tolerability of the study medication was assessed at the end of each study period. The subject was also asked to report intervening adverse events between study visits. The subject was specifically asked about headache, lightheadedness and skin irritation. Intensity of adverse reactions was rated as mild, moderate or severe and the likelihood of drug-relatedness was judged by the investigator. Systemic blood pressure was monitored at all assessment points. Physical examinations and routine laboratory studies were performed prior to study entry and following completion of all study visits.
Study medication
MQX-503, a topical gel formulation of nitroglycerine, was supplied in individual dose Del Pouch applicators containing 0.5 g of gel each or identical applicators containing the placebo gel.
Study protocol
Subjects were placed in a quiet limited-access room with controlled temperature (20-25°C) and humidity for 30 min prior to baseline measurements. The baseline BF was measured three times in the fingers of the subject's non-dominant hand (second through fourth digits), using a Moor Instruments moorLDI scanning laser Doppler instrument and reported in perfusion units (PU). Baseline digital ST was defined using the average of three prechallenge temperature measurements using a thermistor. The treatment gel was applied to the four fingers of the subject's non-dominant hand and rubbed into the fingers for 1 min. The cold challenge procedure was then performed by placing the subject's hand into the cold exposure chamber (−20°C) up to the mid-forearm. The cold challenge was continued for a maximum of 5 min, until the ST fell to 12°C, or until the subject could no longer tolerate the cold. The hand was then removed from the chamber and passively rewarmed in the room environment. The digital temperature at the end of the cold challenge was defined as the minimum ST. The recovery to 50% and 70% of prechallenge digital ST was defined as: Minimum ST+(( prechallenge temperature− minimum ST)×0.5 and 0.7) respectively. The systemic blood pressure, ST and finger BF were determined immediately after exposure and at 5, 15, 25, 35, 45, 55 and 120 min following the cold challenge. During this BF monitoring period, the subject completed pain, numbness and tingling scores.
At the end of the BF monitoring period, there was at least a 1 h interval before the next study period, which proceeded in the same manner as described above. Two challenges and gel applications occurred at each of three study visits (at least 15 h but no more than 4 days apart) for a total of six sessions.
STATISTICAL ANALYSIS
Efficacy and safety analyses were based on the intent-to-treat population defined as all subjects who received at least one dose study medication. Summary statistics, including the mean and SD as well as medians and ranges, are presented for the three groups. Data for each treatment were pooled across sequences and assessments for analysis. We used marginal generalised linear model with binomial distribution and exchangeable correlation structure using generalised estimating equations to account for non-independence of multiple observations per patient and to compare the proportion of subjects achieving baseline BF by dose. Differences in continuous variables between groups were compared via the Kruskall-Wallis test for equality. Contrasts between treatment groups with regard to Raynaud symptoms (tingling, numbness, pain) were made using the Wilcoxon Rank-Sum test.
Time to achieve baseline BF Survival times were estimated using Kaplan-Meier method and were compared using log-rank test. To estimate the relative efficiency of the treatment groups, Cox proportional hazards models were used. Subjects who did not achieve baseline BF were censored at the last measurement of BF. Proportionality of hazards was assessed based on the analysis of Schoenfeld residuals. 15 The HRs were adjusted for type of RP (secondary vs primary) and the baseline BF level (continuous, per 50 PU). Due to the discrete nature of the times, tied failure times were accounted for using marginal calculation assuming that they occurred due to inability to measure precise time of failure, not due to true discreteness of the times. 16 In order to account for the fact that each patient contributed multiple observations, Cox survival model with shared frailty was used and assumes that each patient possesses underlying proneness to achieve the baseline BF modelled as a random effect. 17 For observations that achieved baseline BF at the end of cold challenge (time 0) the distributions are presented by treatment groups and were dropped from the Cox regression models. To assess for carryover effect, a Cox regression was run for second assessment at each visit using time to achieve baseline BF at the first assessment as the predictor.
Missing data
Missing data patterns were assessed using PROC MI in SAS. Two approaches of handling missing data were used. First, complete case analyses were conducted. Cases were called 'nondisputable' if patients achieved baseline BF at earlier times and had missing values at later times. However, if earlier measurements were missing, even if patients achieved baseline BF at later times, the time of that event is 'disputable'. In the complete case analyses, all disputable failures as well as all observations with missing data and without achieving baseline BF were excluded. All main results are based on complete case analyses. Second, assuming that values are missing at random, multiple imputation of missing data using Markov chain Monte Carlo (MCMC) data augmentation method (using other available measures, such as non-missing BF values, to impute the missing values) was performed. 18 
Skin temperature
The actual time of each measurement of ST was used in the analysis of recovery of 50% and 70% ST. Subjects who did not achieve 50% or 70% recovery of ST were censored at the time of their last recorded measurement. Survival times were estimated using Kaplan-Meier method and were compared using log-rank test.
Stata 11 (StataCorp. 2009. Stata Statistical Software: Release 11. College Station, Texas, USA: StataCorp LP) was used for the analyses and SAS V.9.2 for Windows (SAS Institute, Cary, North Carolina, USA) was used for multiple imputations of missing values and for combining the parameter estimates.
RESULTS

Subject characteristics
Overall, 37 subjects were entered into the study, 25 subjects from Johns Hopkins Hosptial (JHH) and 12 from University of Washington (UW). Two subjects withdrew from the study after the first treatment period. A total of 35 subjects completed the study protocol (214 treatment periods, 72 for placebo, 71 for 0.5% gel and 71 for 1.25% gel) and all 37 subjects were included in the intent-to-treat analysis. Subject demographics and baseline data are presented in table 1.
Blood flow
The mean±SD baseline BF for the entire study population was 139.8±105.3 PU and there were no differences between groups (p=0.18, df=2). Subjects with primary RP had higher mean baseline BF compared with those with secondary RP (168.4±135.7 vs 127.4±87.2) but this difference was not statistically significant (p=0.25). There was a significant drop in mean BF after cold challenge in all three groups (mean change from baseline −46.4 ±75.3 PU).
The distribution of patients that achieved baseline BF is represented in table 2. The proportion of subjects who achieved baseline BF was significantly higher in each of the two active arms relative to placebo (placebo: 45.8%, 0.5%: 66.2%, 1.25%: 69%), but the two active arms did not differ significantly from each other (p=0.53). There were no overall differences in the proportion who achieved baseline BF comparing those with primary versus secondary RP (p=0.48) (table 2B). However, the treatment effect was only significant in the primary RP group and significantly attenuated in the secondary RP group (table 2C) .
The proportion, rate and median time of achieving baseline BF in each treatment group is represented in table 3. The proportion of visits where the subject had already achieved baseline BF at the end of cold challenge were five for placebo 15 for 0.5 mg and 13 for 1.25 mg groups. There was a more rapid recovery of BF in the two treatment arms compared with placebo ( figure 1) . As it can be seen in figure 1 , at each point in time, the probability of not achieving baseline BF is greater in the placebo group compared with the treatment groups. The log-rank test yields statistically significant difference among the three groups (χ 2 =6.90 df=2, p=0.032). Table 4 presents the results of the standard Cox regression models. According to the table, active treatment appears superior in achieving baseline BF compared with the placebo with HR=2.02 (95%CI 1.17 to 3.49) for the 1.25% group and HR=1.77 (95%CI 1.03 to 3.07) for the 0.5% groups compared with placebo. The results were not significantly different in the random effect analyses. Furthermore, likelihood ratio test suggests that there is little evidence of high underlying heterogeneity in achieving baseline BF among the patients (adjusted shared frailty model: χ 2 =1.02, p value=0.156). After multiple imputation of missing BF variables, the results appear to be consistent with the main conclusions.
Skin temperature
Almost all subjects achieved 50% and 70% recovery of ST but the proportions of subjects did not differ by treatment group (table 5A and B). There were no significant differences between treatment groups with regard to time to achieve either 50% or 70% of baseline ST. The results of log-rank test comparing three doses suggest that the doses are not significantly different from each other in achieving 50% (p value=0.358) or 70% (p value=0.354) of baseline temperature. After adjusting for the baseline ST using Cox regression with shared frailty, the results were consistent with no difference among three groups (χ 2 Wald test with 2 degrees of freedom=0.4, p value=0.820 and 0.803, respectively).
Symptoms
Overall the median baseline symptom scores were all zero (see table 1 ) and the within-treatment group means were similarly near zero (data not shown), indicating a lack of symptoms at baseline. There was an overall increase in each of the three mean symptom scores after the cold challenge procedure (data not shown), but median symptom score values remained zero for all symptoms at all time points. There was a significant increase in the mean % change (±SD) tingling score in the 0.5% treatment group at end of cold challenge ( placebo: 66.4 ±146.5; 0.5%: 143.3±236.5 ( p=0.04), 1.25%: 107.6±222.8 (p=0.27)); all other comparisons with placebo for pain, tingling and numbness scores were not significant. 
Safety
There were no serious adverse events that occurred during this study. The most common adverse events included headache (three subjects), lightheadedness (two subjects) and dizziness (two subjects). Overall, adverse events were no more common in either of the treatment groups compared with placebo. However, both occurrences of lightheadedness occurred in subjects receiving active treatment (either 0.5% or 1.25%). Two of the subjects' headaches and one episode of lightheadedness were thought to be possibly related to the treatment by the physician. The baseline blood pressure for the whole group was 127/76. No group at any time point had >5% mean change in systolic or diastolic blood pressures. Although there were some statistical differences between the groups in per cent change in systolic blood pressure (−3.86% change in systolic blood pressure in the 0.5% group and −2.55% in the 1.25% group at 15 min and −4.25% in the 0.5% group at 55 min), this was not a consistent difference and the differences were not thought to be clinically relevant. There were no differences in percentage change in blood pressure between treatment groups at either time point (15 and 55 min). Two subjects discontinued the study due to adverse events. One patient developed hypertension after stopping calcium channel blocker therapy (although therapy had been instituted for RP and not a known history of hypertension). The second subject developed some paresthesias of the arm after the second visit and withdrew from the study; this subject received 1.25% gel during that visit. Figure 1 Kaplan-Meier curves of estimated probabilities of not achieving baseline blood flow by treatment groups (assuming no correlation in study periods within each patient, N=179). 
DISCUSSION
This study demonstrates an improvement in digital BF in those subjects treated with MQX-503 compared with placebo in a laboratory-based investigation. This difference was noted in both the 0.5% and 1.25% preparation, with no dose-response effect noted. The study medication was well tolerated with no serious adverse events and no difference in frequency of mild to moderate adverse events. There were a few instances of headache and lightheadedness that may have been related to the active treatment. The rates of side effects seen in this study, if related to the study drug, were remarkably lower than the rates in other published studies of nitroglycerine preparations. The first placebo-controlled trial with a clinical endpoint suggested benefit of topical nitroglycerine in Raynaud attack frequency, attack severity and digital ulcers. 8 Anderson et al 4 showed improvement in vasodilatory response as measured by laser Doppler in subjects treated with local topical nitroglycerine therapy, although the placebo ointment also showed some benefit. No other outcome assessments were performed and there was no mention of tolerability or side effects. A preparation of nitroglycerine tape was examined in 25 subjects with scleroderma-associated RP in an open label study using thermography as the main outcome measure. This study showed an increase in finger temperature, but a significant fall in systolic blood pressure and 25% of subjects experienced headache and flushing. 3 In the current study, since subjects receive two doses over two assessments per treatment visit, there could be a concern that the effects of the first dose could linger into the second assessment timeframe, or even into the next visit. This is unlikely given the 1-4 min half-life of nitroglycerine and the high volatility of nitroglycerine, making what has not been absorbed by the skin evaporate within 5 min. Human studies confirm that the pharmacodynamic effects of MQX-503 last only 45 min. In addition, no significant carry over effect was found in this analysis (data not shown).
This study also suggested that the effectiveness of this preparation may be more pronounced in those with primary compared with secondary RP, although the study may have been underpowered to see smaller effect sizes in these subgroups. This would be consistent with other therapies, where the effect is seen primarily in milder disease states. Other than type of Raynaud, we did not have any other baseline measures of Raynaud severity to test this further, but since only half of the subjects had received prior therapy for RP, this was likely a mild group of subjects.
This study demonstrated an improvement in BF, but no differences in ST. This disparity has been noted in other studies. In another study of subjects with primary and secondary RP and healthy controls, there was a poor correlation between thermography and laser Doppler imaging. 19 The authors suggested that 
